Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Issue 1 (3rd June 2015)

• Record Type: Journal Article
• Authors: Birdwell, KA; Decker, B; Barbarino, JM; Peterson, JF; Stein, CM; Sadee, W; Wang, D; Vinks, AA; He, Y; Swen, JJ; Leeder, JS; van Schaik, RHN; Thummel, KE; Klein, TE; Caudle, KE; MacPhee, IAM
• Is Part Of: Clinical pharmacology & therapeutics. Volume 98:Issue 1(2015:Jul.)
• Page Start: 19
• Page End: 24
• Publication Date: 2015-06-03
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.113
• Languages: English
• ISSNs: 0009-9236

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose‐adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on <italic>CYP3A5</italic> genotype when known (updates at <ext-link ext-link-type="uri" xlink:href="http://www.pharmgkb.org" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">www.pharmgkb.org</ext-link>).</p> </abstract>